Today's Health Winners and Losers
Shares of Monogram Biosciences (MGRM) were among the best-performing health-related stocks Monday, vaulting 38% after the maker of medical tests posted a narrower first-quarter loss and announced a collaboration agreement with Pfizer (PFE).
Monogram reported a loss of $3.4 million, or 3 cents a share, on revenue of $13.2 million. Excluding stock-based compensation costs, the company recorded a loss of $1.5 million, or 1 cent a share. Last year, the company posted a first-quarter loss of $7.4 million, or 6 cents a share, on revenue of $10 million. Excluding items, the year-ago loss was $4.1 million, or 3 cents a share.
Pfizer will invest $25 million in Monogram as part of the companies' collaboration. The investment will "provide a substantial injection of capital to facilitate our continued growth and development and also represents a huge endorsement of our role as the partner of choice for companies with significant HIV development programs," Monogram said. The investment is being made through a 3% convertible note due 2010. The multi-year agreement aims to help Monogram make its HIV co-receptor Tropism assay available for patient use on a worldwide basis. Shares of Monogram were trading up 65 cents to $2.34.
Integra LifeSciences (IART) fell 4% after the medical-device maker posted soft revenue for the first quarter and offered a second-quarter revenue guidance that fell short as well. The company's first-quarter earnings were $8.7 million, or 28 cents a share, up from $8.4 million, or 26 cents a share, a year earlier. Excluding restructuring charges, Integra posted earnings of 31 cents a share. Revenue rose to $77.1 million from $65.8 million. Analysts polled by Thomson First Call expected earnings of 28 cents a share and revenue of $80.4 million.Looking ahead, Integra sees second-quarter earnings of 31 cents to 34 cents a share, excluding restructuring charges. The company predicts revenue of $87 million to $92 million. Analysts project earnings of 32 cents a share on revenue of $92.6 million. Shares were down $1.90 to $40.92.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV